Skip to search formSkip to main contentSkip to account menu

[ LAB] SCH66336

Known as: SCH-66336, SCH66336, SCH 66336 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

lonafarnib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation…
The identification of signaling pathways critical to myeloma growth and progression has yielded an array of novel agents with… 
Highly Cited
2005
Highly Cited
2005
Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.
Highly Cited
2004
Highly Cited
2004
Protein Farnesyltransferase Inhibitor (SCH 66336) Abolishes NF-κB Activation Induced by Various Carcinogens and Inflammatory Stimuli Leading to Suppression of NF-κB-regulated Gene Expression and Up…
Ras farnesyltransferase inhibitor (FTI) exhibit antiproliferative and antiangiogenic effects through a mechanism that is poorly… 
Review
2001
Review
2001
Current status of clinical trials of farnesyltransferase inhibitors
Farnesyltransferase inhibitors represent a new class of agents that target signal transduction pathways responsible for the… 
Highly Cited
2001
Highly Cited
2001
Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.
PURPOSE A single-agent dose-escalating phase I and pharmacokinetic study on the farnesyl transferase inhibitor SCH 66336 was… 
Highly Cited
2001
Highly Cited
2001
The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
P-glycoprotein (Pgp)-mediated drug efflux is a major factor contributing to the variance of absorption and distribution of many… 
Highly Cited
2000
Highly Cited
2000
A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity.
Farnesyl protein transferase (FT), an enzyme that catalyzes the first step in the posttranslational modification of ras and a… 
Highly Cited
2000
Highly Cited
2000
Comparison of potential markers of farnesyltransferase inhibition.
Farnesyltransferase inhibitors (FTIs) were developed to target abnormal signaling pathways that are commonly activated in… 
Highly Cited
2000
Highly Cited
2000
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo
Purpose: SCH66336 is an orally active, farnesyl protein transferase inhibitor. SCH66336 inhibits ras farnesylation in tumor cells… 
Highly Cited
1998
Highly Cited
1998
(+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein…
We have previously shown that appropriate modification of the benzocycloheptapyridine tricyclic ring system can provide potent… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)